Frazier Life Sciences Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Frazier Life Sciences Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$135M	Hold	12,466,489	–	–	2.95%	9
2026 Q1	$139M	Hold	12,466,489	–	–	3.56%	7
2025 Q4	$207M	Hold	12,466,489	–	–	5.55%	6
2025 Q3	$147M	Hold	12,466,489	–	–	4.4%	6
2025 Q2	$120M	Buy	12,466,489 +2,357,210	+23%	+$13M	4.78%	6
2025 Q1	$63.4M	Hold	10,109,279	–	–	2.9%	10
2024 Q4	$82.1M	Hold	10,109,279	–	–	3.41%	11
2024 Q3	$183M	Hold	10,109,279	–	–	7.33%	3
2024 Q2	$104M	Hold	10,109,279	–	–	4.87%	5
2024 Q1	$107M	Hold	10,109,279	–	–	4.53%	6
2023 Q4	$92.3M	Hold	10,109,279	–	–	4.93%	7
2023 Q3	$105M	Hold	10,109,279	–	–	6.96%	5
2023 Q2	$145M	Buy	10,109,279 +1,702,127	+20%	+$19.6M	8.65%	3
2023 Q1	$60M	Hold	8,407,152	–	–	4.35%	8
2022 Q4	$94.3M	Hold	8,407,152	–	–	5.86%	7
2022 Q3	$93.2M	Buy	8,407,152 +2,579,737	+44%	+$24.6M	7.17%	3
2022 Q2	$49.2M	Hold	5,827,415	–	–	4.64%	7
2022 Q1	$79.3M	Buy	+5,827,415	New	+$94.1M	6.76%	2

Other funds holding PHAT

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Frazier Life Sciences Management's PHAT Position: Q2 2026 in Review

Frazier Life Sciences Management held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 12,466,489 shares worth $135M. The position accounts for 2.95% of the portfolio, ranked #9.

Frazier Life Sciences Management first reported a position in PHAT in Q1 2022 and has held it in 18 quarters since. The position peaked at $207M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Frazier Life Sciences Management held 12,466,489 shares of Phathom Pharmaceuticals worth $135M as of Q2 2026.
Frazier Life Sciences Management left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
Phathom Pharmaceuticals made up 2.95% of Frazier Life Sciences Management's portfolio in Q2 2026, its #9 holding.
Frazier Life Sciences Management first reported a position in Phathom Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
Frazier Life Sciences Management's Phathom Pharmaceuticals position peaked at $207M in Q4 2025.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.